Results 151 to 160 of about 3,014 (182)

Erdafitinib

Reactions Weekly, 2022
openaire   +2 more sources

Erdafitinib

Reactions Weekly, 2023
openaire   +2 more sources

Erdafitinib (Balversa)

Canadian Journal of Health Technologies
Canada’s Drug Agency (CDA-AMC) recommends that Balversa should be reimbursed by public drug plans for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (UC) if certain conditions are met. Balversa should only be covered to treat patients with a diagnosis of locally advanced unresectable or metastatic UC harbouring ...
openaire   +1 more source

Erdafitinib (Balversa) for Urothelial Carcinoma

The Medical Letter on Drugs and Therapeutics
Erdafitinib (Balversa – Janssen), an oral kinase inhibitor, has received full approval from the FDA for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3 (fibroblast growth factor receptor) genetic alterations who had disease progression on or after at least one prior line of systemic therapy.
openaire   +2 more sources

Biomolecular Interactions and Binding Dynamics of Tyrosine Kinase Inhibitor Erdafitinib, With Human Serum Albumin

Journal of Biomolecular Structure and Dynamics, 2021
Mohd Aamir Qureshi, Saleem Javed, Mohd Amir   +2 more
exaly  

Metabolism and Disposition in Rats, Dogs, and Humans of Erdafitinib, an Orally Administered Potent Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor

Xenobiotica, 2021
Italo Poggesi, Filip Cuyckens, Laurent Leclercq   +2 more
exaly  

Avelumab/erdafitinib

Reactions Weekly, 2023
openaire   +1 more source

Erdafitinib en carcinoma urotelial

Panorama Actual del Medicamento
Erdafitinib es un nuevo inhibidor altamente selectivo y potente de la tirosina cinasa de todas las proteínas de la familia de receptores del factor de crecimiento de fibroblastos (FGFR). Las mutaciones activadoras y otras translocaciones y fusiones en los genes FGFR se han asociado con la patogénesis, progresión neoplásica y vascularización tumoral en ...
openaire   +1 more source

Study of Erdafitinib Stress Degradation Behavior Using HPLC-UV Analysis and Multistage Fragmentation Ion Trap Mass Spectrometry

Microchemical Journal, 2022
Fathalla Belal, Tarek Elawady, Alaa Khedr   +2 more
exaly  

Erdafitinib in Urothelial Carcinoma

New England Journal of Medicine, 2019
Guru, Sonpavde, Gottfrid, Sjödahl
openaire   +3 more sources